{
    "Trade/Device Name(s)": [
        "Xprecia Prime Coagulation System",
        "Xprecia Prime INR Coagulation Analyzer",
        "Xprecia Prime PT/INR Test Strips",
        "Xprecia Systems PT Controls"
    ],
    "Submitter Information": "Universal Biosensors Pty Ltd",
    "510(k) Number": "K230802",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060978"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GJS"
    ],
    "Summary Letter Date": "March 15, 2023",
    "Summary Letter Received Date": "March 23, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7750"
    ],
    "Regulation Name(s)": [
        "Prothrombin Time Test"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin time",
        "INR (International Normalized Ratio)",
        "Seconds"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [
        "Fingerstick"
    ],
    "Instrument(s)/Platform(s)": [
        "Xprecia Prime Coagulation Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical technology",
        "Amperometric detection of thrombin activity"
    ],
    "Methodologies": [
        "Prothrombin time assay",
        "Coagulation testing"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strips",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Xprecia Prime Coagulation System for point-of-care measurement of prothrombin time (INR) using electrochemical detection from fingerstick whole blood.",
    "Indications for Use Summary": "For determination of INR to monitor oral anticoagulation therapy with warfarin in stable adult patients using fresh capillary whole blood from fingerstick in professional healthcare settings, including CLIA Waived and point-of-care environments.",
    "fda_folder": "Hematology"
}